Compensation for Research Participation: Should We Worry About Too Little Rather Than Too Much?
One of a series of live panels recorded at the WCG Patient Advocacy Forums in Washington D.C. in October, 2019.
Historically, IRBs have been reluctant to support compensation for clinical trial participants. But attitudes around compensation have changed, partly due to the urging of patient advocates, partly because regulators increasingly recognize the role of compensation in research studies and, perhaps most important, because patients are recognized as team members rather than as subjects.
This discussion featured Elisabeth M. Oehrlein, senior director, National Health Council, Jeanne Regnante, SVP, Community Education and Chair - Diverse Cancer Communities Working Group and National Minority Quality Forum and Leslie Hanrahan, SVP, Lupus Foundation of America. David Borasky, WCG’s VP of IRB compliance, moderated.
Click the slides above, or download the PDF to read insights on this topic from patients, patient advocates, and industry leaders.